Immunome issues 4,425,487 shares to Bristol-Myers Squibb in unregistered sale
IMNM•Immunome issued 4,425,487 shares to Bristol-Myers Squibb in connection with a license amendment, receiving $20 million and eliminating all milestone, royalty and other payment obligations to BMS.
1. Shares issued under amendment
Immunome issued 4,425,487 common shares to Bristol-Myers Squibb in an unregistered sale tied to a license amendment. Consideration included $20 million in cash, and the amendment eliminated all milestone, royalty or other payment obligations to BMS. Immunome committed to file a resale registration statement for the shares by Nov. 16, 2026; the shares were issued under the Securities Act Section 4(a)(2) private placement exemption.
